Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ Thresholds for decision

Joint Bone Spine

Volumn 80, Issue 1, 2013, Pages 64-69

  Alzahouri, Kazem ^a,c   Bahrami, Stéphane ^a,b   Durand Zaleski, Isabelle ^a,b   Guillemin, Francis ^c   Roux, Christian ^d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CHU NANCY BRABOIS   (France)

^d université Paris Cité   (France)

Author keywords

Alendronate; Cost effectiveness; FRAX ; Hip fracture; Osteoporosis

Indexed keywords

ALENDRONIC ACID;

AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FRANCE; HEALTH CARE COST; HIP FRACTURE; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; POPULATION; POSTMENOPAUSE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HIP FRACTURES; HUMANS; MARKOV CHAINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT;

EID: 84872873055     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.01.001     Document Type: Article

References (44)

1. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
2. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
3. Kanis J.A., Johnell O., Oden A., et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
4. Kanis J.A., Burlet N., Cooper C., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
5. Kanis J.A., Adams J., Borgström F., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008, 42:4-15.
6. Tosteson A.N., Jonsson B., Grima D.T., et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001, 12:849-857.
7. Tosteson A.N.A., Melton L.J., Dawson-Hughes B., et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447.
8. Kanis J.A., McCloskey E.V., Johansson H., et al. National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX™ - assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408.
9. Drummond M., Barbieri M., Cook J., et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force Report. Value Health 2009, 12:409-418.
10. Agence française de sécurité sanitaire des produits de santé [French Health Products Safety Agency]. Traitement médicamenteux de l'ostéoporose post-ménopausique. 2006; Accessed. [01/10/2010]. http://www.afssaps.fr/content/download/7843/78935/version/5/file/ostemrec.pdf.
11. Bliuc D., Nguyen N.D., Milch V.E., et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
12. Sernbo I., Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 1993, 3:148-153.
13. Schott A.M., Ganne C., Hans D., et al. Which screening strategy using BMD measurements would be most cost-effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 2007, 18:143-151.
14. Baudoin C., Fardellone P., Bean K., et al. Clinical outcomes and mortality after hip fracture: a 2-year follow-up study. Bone 1996, 18:149S-157S.
15. Rapp K., Lamb S.E., Becker C., et al. Hip fractures in institutionalized elderly people: incidence rates and excess mortality. J Bone Miner Res 2008, 23:1825-1831.
16. Cranney A., Guyatt G., Griffith L., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570-578.
17. Stevenson M., Jones M.L., De Nigris E., et al. A systematic review and economic evaluation of alendronate. etidronate. risedronate. raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005, 9:1-160.
18. Geusens P.P., Roux C.H., Reid D.M., et al. Drug Insight: choosing a drug treatment strategy for women with osteoporosis - an evidence-based clinical perspective. Nat Clin Pract Rheumatol 2008, 4:240-248.
19. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
20. Johnell O., Jonsson B., Jönsson L., et al. Cost-effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003, 21:305-314.
21. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
22. Weycker D., Macarios D., Edelsberg J., et al. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007, 18:271-277.
23. Tosteson A.N., Grove M.R., Edelsberg J., et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216.
24. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
25. Strom O., Borgstrom F., Kanis J.A., et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009, 20:23-34.
26. Cotté F.E., Fardellone P., Mercier F., et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010, 21:145-155.
27. Hiligsmann M., Ethgen O., Richy F., et al. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008, 82:288-292.
28. Macran S., Weatherly H., Kind P. Measuring population health: a comparison of three generic health status measures. Med Care 2003, 41:218-231.
29. Burstrom K., Johannesson M., Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001, 55:51-69.
30. Borgstrom F., Zethraeus N., Johnell O., et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006, 17:637-650.
31. Brazier J.E., Green C., Kanis J.A. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002, 13:768-776.
32. Strom O., Borgstrom F., Zethraeus N., et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008, 79:269-280.
33. Peasgood T., Herrmann K., Kanis J.A., et al. An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 2009, 20:853-868.
34. Kanis J.A., Johnell O., Oden A., et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int 2004, 15:20-26.
35. Schousboe J.T., Nyman J.A., Kane R.L., et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005, 142:734-741.
36. French Senate. La prise en charge de la dépendance et la création du cinquième risque. 2008; Accessed [01032011]. http://www.senat.fr/rap/r07-447-1/r07-447-1.html.
37. Borgstrom F., Johnell O., Kanis J.A., et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006, 17:1459-1471.
38. Eichler H.G., Kong S.X., Gerth W.C., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
39. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:nihpa40967.
40. Bolland M.J., Grey A.B., Gamble G.D., et al. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010, 95:1174-1181.
41. Tremollières F.A., Pouillès J.M., Drewniak N., et al. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX™ tool. J Bone Miner Res. 2010, 25:1002-1009.
42. van Geel T.A.C.M., van den Bergh J.P.W., Dinant G.J., et al. Individualizing fracture risk prediction. Maturitas 2010, 65:143-148.
43. Nguyen T., Sambrook P., Kelly P., et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993, 307:1111-1115.
44. Kanis J.A., Oden A., Johnell O., et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporo Int 2001, 12:417-427.